Gastroenterology Research and Practice / 2009 / Article / Tab 1

Clinical Study

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life

Table 1

Patient characteristics at baseline.

Patient IDGender/Age (years)/DiagnosisBody mass index ( )Small bowel (cm)Colon-in-cont. (%)Time since last surgery (years)Wet weight intake (kg/d)Fecal wet weight excretion (kg/d)Parenteral fluid (L/d)Diet energy intake (MJ/d)Fecal energy excretion (MJ/d)Patenteral energy (MJ/d)Duration of HPN (years)Time on GLP-2 (days of )

HRMF/47/CD21.315002.55.23.71.013.57.10.82.5
LMM/27/CD21.070752.53.92.32.311.86.06.42.5
OBM/49/CD25.5150011.63.11.30.513.24.60.011.6 Abd. Pain
GLM/53/CD17.3180020.63.21.6no16.84.4nono
JPM/24/CD20.41301002.33.10.71.816.44.64.52.3 Abd. Pain
EFPF/55/CD17.55000.52.24.93.18.07.15.51.7 unrel. Feedback
JEM/44/UC compl.27.220001.65.93.9no13.85.5nono
JHJM/55/UC compl.22.220002.34.61.91.317.82.80.42.3
UDJF/50/UC compl25.815000.92.82.22.98.82.22.72.9
JVM/67/CD22.6180012.18.77.1no28.218.1nono
FVLM/59/CD20.129005.83.11.2no7.81.3nono

M male, F female, CD Crohns disease, UC compl. Ulcerative colitis complications, Abd. Pain Abdominal pain, Unrel. Feedback Unreliable feedback.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.